@entity1507 therapy for XXXX .

@entity1 @entity12118 @entity3362 @entity26 @entity3361 @entity1507 @entity1459 @entity3979 @entity951 @entity460 @entity299 @entity583 @entity551
The beneficial effects on @entity3362 are related to a combination of coronary and non-coronary effects of the drugs. @entity1 with different forms of @entity299 may respond differently. For instance, in a @entity1 with @entity1459 due to @entity3361 , @entity3362 will reverse or prevent @entity3361 . In contrast, the @entity1 with severe @entity3979 and reproducible @entity951 during exercise, may obtain relief because @entity3362 decrease venous return, left ventricular size and left ventricular pressure, thus decreasing myocardial @entity26 demands. @entity3362 can be used to treat @entity1 with @entity951 , @entity1459 and @entity583 . In @entity1 with @entity951 , oral @entity1507 preparations with sustained-release action have been shown to decrease the indices of myocardial @entity26 demand for up to 12 h. In @entity1 with @entity1459 , intravenous @entity3362 usually relieve symptoms in @entity1 refractory to oral therapy. In @entity1 with @entity583 , early administration with intravenous @entity3362 may benefit @entity1 as suggested by randomized prospective trials. @entity1507 tolerance and @entity1507 dependence does not seem to be an important clinical problem. Perhaps this is related to the way the drug is given, i.e. intermittently. In some instances, however, when high doses are used or the drug is administered intravenously or by the transdermal route, constant levels of @entity12118 may be attained and the @entity1 may develop tolerance. Although @entity3362 are effective drugs, it is native to think that they will be used alone to manage the complex problems associated with @entity299 . Other than @entity551 and adverse effects of the drug, there seems to be no contraindication to the combination of @entity3362 with @entity460 antagonists or beta blockers.
